Search clinical trials for: ABI-007 (Abraxane)

Total 4573 results

University Health Network, Toronto
Celgene Corporation

Completed

A Phase I Trial of Abraxane, Cisplatin and 5-Fluorouracil Along With Chemoradiotherapy in Advanced Head and Neck Cancer

Head and Neck Cancer

Canada
Washington University School of Medicine

Terminated

Phase I/II Study of Abraxane in Recurrent and Refractory Lymphoma

Lymphoma, Non-Hodgkin | Hodgkin Disease

United States
Celgene

Completed

Phase 2 Study With Abraxane (Nab®Paclitaxel) in Metastatic Colorectal Cancer

Colorectal Neoplasms

France
Celgene

Completed

An Open Label Study in Patients With Advanced NSCLC With ABI-007(Abraxane) in Combination With Carboplatin

Non-Small Cell Lung Cancer (NSCLC)

Russian Federation
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

Recurrent Ovarian Carcinoma | Fallopian Tube Carcinoma | Primary Peritoneal Carcinoma

United States
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
Gynecologic Oncology Group
National Cancer Institute (NCI)

Completed

ABI-007 in Treating Patients With Persistent or Recurrent Cervical Cancer

Cervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Squamous Cell Carcinoma | Recurrent Cervical Carcinoma | Cervical Small Cell Carcinoma

United States
Mayo Clinic
National Cancer Institute (NCI)

Terminated

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Relapsed or Refractory Multiple Myeloma

Refractory Plasma Cell Myeloma

United States
University of Alabama at Birmingham
Susan G. Komen Breast Cancer Foundation; Daiichi Sankyo UK Ltd.; Triple Negative...

Completed

Abraxane With or Without Tigatuzumab in Patients With Metastatic, Triple Negative Breast Cancer

Breast Cancer | Metastatic Breast Cancer | Triple Negative Breast Cancer | Stage IV Breast Cancer

United States
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
University of Michigan Rogel Cancer Center
Celgene Corporation

Terminated

Trial of Combination ABI-007, Carboplatin, and Gemcitabine for First Line Treatment of Advanced Urothelial Cancer

Bladder Cancer | Urothelial Cancer

United States
Celgene

Completed

Abraxane in Treatment of Metastatic Breast Cancer

Metastatic Breast Cancer

Austria
Mt. Sinai Medical Center, Miami
Bayer; Celgene Corporation

Completed

A Phase II Trial OF Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma

Malignant Melanoma

United States
Case Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung Carcinoma

Stage I Non-Small Cell Lung Cancer | Stage II Non-Small Cell Lung Cancer

United States
Celgene

Terminated

Use of ABI-007 for the Prevention of Vascular Access Graft Failure in Patients Undergoing Hemodialysis

Hemodialysis Graft Dysfunction

United States
Emory University

Completed

Phase II Neoadjuvant Trial of Trastuzumab in Combination With Dose-Dense ABI-007 (Abraxane™)

Breast Cancer

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
Celgene Corporation

Withdrawn

Study to Determine Efficacy and Safety of CC-486 With Nab-Paclitaxel Versus Nab-Paclitaxel in Patients With Chemotherapy naïve Metastatic Melanoma

Metastatic Melanoma
Celgene

Withdrawn

A Trial of ABI-010 & ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Solid Tumor

United States
Celgene

Terminated

First Line Therapy for Patients With Metastatic Breast Cancer

Metastatic Breast Cancer

Canada
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
M.D. Anderson Cancer Center
Celgene

Completed

Abraxane in CIMP-High Colorectal and Small Bowel Adenocarcinomas

Colorectal Cancer | Cancer of Gastrointestinal Tract

United States
IRCCS Eugenio Medea

Recruiting

Pragmatic Abilities in Children With Acquired Brain Injury (ABIabc)

Acquired Brain Injury | Pragmatic Communication Disorder

Italy
Celgene Corporation

Completed

Study of ABI-007 and Taxol in Patients With Metastatic Breast Cancer

Breast Neoplasms | Metastases, Neoplasm

United States
Celgene Corporation

Completed

Use of Nanoparticle Paclitaxel (ABI-007) for the Prevention of In-Stent Restenosis (SNAPIST-III)

Coronary Restenosis
SCRI Development Innovations, LLC
Celgene

Completed

Study of Nab-Paclitaxel and Ramucirumab as Second-line Treatment for Patients With Metastatic Gastroesophageal Cancer

Gastroesophageal Cancer

United States
Celgene
University of Arizona

Completed

A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma

Malignant Melanoma

Canada, United States, Australia, United Kingdom, France, Italy, Spain, Germany, Netherlands
Celgene

Completed

Trial of ABI-007 in Previously Treated Patients With Metastatic Melanoma

Melanoma | Metastases

United States
Celgene Corporation

Completed

ABI-007 in Taxol Resistant Patients With Metastatic Breast Cancer

Breast Neoplasms | Metastases, Neoplasm

United States
Celgene Corporation

Completed

A Trial of ABI-007 in Patients With Advanced Non-Hematologic Malignancies

Neoplasms | Metastases, Neoplasm

United States
Taiho Pharmaceutical Co., Ltd.

Completed

Phase II Study of ABI-007 for Gastric Cancer

Gastric Cancer

Japan
University of Washington
National Cancer Institute (NCI); Celgene Corporation

Completed

Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Previously Treated Advanced Non-small Cell Lung Cancer

Recurrent Non-Small Cell Lung Carcinoma | Stage IV Non-Small Cell Lung Cancer

United States
National Research Council, Spain
Hospital Universitario 12 de Octubre

Completed

Food Anthocyanins and Flavanols as a Strategy for a Healthy Ageing: Cardiovascular Health and Cognitive Performance (POLYAGE)

Healthy Aging

Spain
Celgene Corporation

Terminated

Prevention of Restenosis Following Revascularization

Vascular Disease, Peripheral

United States
Celgene Corporation

Completed

Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Cancer

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Nab-Paclitaxel in Treating Older Patients With Locally Advanced or Metastatic Breast Cancer

Recurrent Breast Carcinoma | Stage IV Breast Cancer AJCC v6 and v7 | Stage III Breast Cancer AJCC v7 | Stage IIIA Breast Cancer AJCC v7 | Stage IIIB Breast Cancer AJCC v7 | Stage IIIC Breast Cancer AJCC v7 | Metastatic Breast Carcinoma | Locally Advanced Breast Carcinoma

United States
Loyola University
Genentech, Inc.; Celgene Corporation

Completed

Carboplatin, Paclitaxel, and Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

United States
Celgene

Completed

A Study to Collect Survival Data on Patients Previously Enrolled in Abraxane Pancreatic Cancer Study CA046.

Pancreatic Cancer

United States, Canada, Spain, Australia, France, Germany, Austria, Italy, Ukraine
Celgene

Completed

Phase II Trial Comparing ABI-007 (Abraxane®, Nab®-Paclitaxel) to Taxotere in First Line Therapy of Patients With Stage IV Breast Cancer

Metastatic Breast Cancer

Ukraine
Mayo Clinic
National Cancer Institute (NCI)

Withdrawn

Paclitaxel Albumin-Stabilized Nanoparticle Formulation After Cisplatin-Based Chemotherapy and Surgery in Treating Patients With High-Risk Bladder Cancer

Recurrent Bladder Urothelial Carcinoma | Stage IV Bladder Urothelial Carcinoma

United States
Chinese PLA General Hospital

Unknown

Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer (NAPSPAC)

Advanced Pancreatic Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Nab-Paclitaxel, Capecitabine, and Radiation Therapy Following Induction Chemotherapy in Treating Patients With Locally Advanced Pancreatic Cancer

Pancreatic Adenocarcinoma | Stage III Pancreatic Cancer AJCC v6 and v7 | Locally Advanced Pancreatic Adenocarcinoma | Borderline Resectable Pancreatic Adenocarcinoma | Stage II Pancreatic Cancer AJCC v6 and v7 | Stage IIA Pancreatic Cancer AJCC v6 and v7 | Stage IIB Pancreatic Cancer AJCC v6 and...

United States
Celgene

Terminated

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

Ovarian Neoplasms | Fallopian Tube Neoplasms | Peritoneal Neoplasms

United States
Anne Noonan
National Cancer Institute (NCI)

Recruiting

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Stage IV Pancreatic Cancer AJCC v8 | Metastatic Pancreatic Adenocarcinoma

United States
Eleven Biotherapeutics

Completed

Phase 1 Study for Safety and Tolerability of EBI-005 Topically Administered to Eyes of Healthy Adult Subjects (EBI-005-1)

Dry Eye

United States
Celgene

Completed

Albumin-bound Paclitaxel (ABI-007) for Patients With Advanced Non-Small Cell Lung Cancer

Non-Small Cell Lung Carcinoma

United States, Canada
Celgene

Terminated

Weekly vs. Every 2 Week vs. Every 3 Week Administration of ABI-007 (Abraxane)/Bevacizumab Combination in Metastatic Breast Cancer

Breast Neoplasms | Neoplasm Metastasis

United States, Puerto Rico

Search clinical trials for: ABI-007 (Abraxane)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Bulgaria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations